Loading…

ORIGINAL ARTICLE: REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY

Peritoneal dissemination of malignancy is usually considered incurable. The purpose of the present study was to evaluate the efficacy of intraperitoneal chemohyperthermia and cytoreductive surgery. The present article is a retrospective review of prospectively recorded data in 60 patients who underw...

Full description

Saved in:
Bibliographic Details
Published in:ANZ journal of surgery 2006-03, Vol.76 (3), p.156-161
Main Authors: Reema Hadi, Vanessa Saunders, Olga Utkina, Philip Clingan, Peter Kam, Links, Matthew, Morris, David L
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 161
container_issue 3
container_start_page 156
container_title ANZ journal of surgery
container_volume 76
creator Reema Hadi
Vanessa Saunders
Olga Utkina
Philip Clingan
Peter Kam
Links, Matthew
Morris, David L
description Peritoneal dissemination of malignancy is usually considered incurable. The purpose of the present study was to evaluate the efficacy of intraperitoneal chemohyperthermia and cytoreductive surgery. The present article is a retrospective review of prospectively recorded data in 60 patients who underwent 71 peritonectomy procedures between January 1996 and May 2004. Hospital records, a database and department notes were studied. Conditions treated were pseudomyxoma peritoneii (PMP) and appendiceal cancer (23), mesothelioma (7), colorectal cancer (CRC, 15), ovarian cancer (6) and other forms of malignancy (9). Following cytoreductive surgery, early postoperative intraperitoneal chemotherapy (EPIC) was given in 47 procedures, five with added i.v. mitomycin C. In 34 procedures, heated intraperitoneal chemotherapy (HIPEC) was administered. A policy change was made from intravenous to intraperitoneal mitomycin C chemotherapy in December 2001. Peritoneal cancer index (PCI) was calculated for all procedures. Of the procedures, 23 had PCI 20. The median operation time was 9 h. Blood units transfused and length of hospital stay have declined. Mortality was 4/60 patients (6.7%), caused by pancytopenia and sepsis. Morbidity occurred in 28/71 procedures. The 3-year survival rate for the HIPEC group was 71% compared with 28% for the no HIPEC group. In the complete excision group, the 3-year survival rate was 52% compared with 13% for the incomplete excision group. The 3-year survival rate for PMP and appendiceal cancer was 74%. The 2-year survival rate for ovarian cancer was 67%, mesothelioma 57%, and CRC 50%, respectively. Morbidity is significantly associated with duration of surgery and units of blood transfused. Our findings are consistent with the international experience in patients treated with combined peritonectomy and HIPEC. [PUBLICATION ABSTRACT]
doi_str_mv 10.1111/j.1445-2197.2006.03579.x
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_20863518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20863518</sourcerecordid><originalsourceid>FETCH-LOGICAL-p588-df6e57b71474841e4105c5ee7a856a6f5fd42b80fd12be93ba1303a3652666b3</originalsourceid><addsrcrecordid>eNpdT8FKw0AUXMSCtRX8hOLBW-K-ffve7h5DqDUQLNTew6bZgCE2tWvAzzdg8eBcZmCGYUaIFcgUJjx1KWhNiQJnUiUlpxLJuPT7Ssz_jOuLBo14I25j7KQEZkdzcb_dFZviNStX2W5f5OV6KWat72O4u_BCvD2v9_lLUm43RZ6VyYmsTZqWA5nagDbaaggaJB0oBOMtseeW2kar2sq2AVUHh7UHlOiRSTFzjQvx-Nt6Og-fY4hf1cd7PIS-98cwjLFS0jIS2Cn48C_YDeP5OC2rwFmF0z2FP-fGRWs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198232192</pqid></control><display><type>article</type><title>ORIGINAL ARTICLE: REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Reema Hadi ; Vanessa Saunders ; Olga Utkina ; Philip Clingan ; Peter Kam ; Links, Matthew ; Morris, David L</creator><creatorcontrib>Reema Hadi ; Vanessa Saunders ; Olga Utkina ; Philip Clingan ; Peter Kam ; Links, Matthew ; Morris, David L</creatorcontrib><description>Peritoneal dissemination of malignancy is usually considered incurable. The purpose of the present study was to evaluate the efficacy of intraperitoneal chemohyperthermia and cytoreductive surgery. The present article is a retrospective review of prospectively recorded data in 60 patients who underwent 71 peritonectomy procedures between January 1996 and May 2004. Hospital records, a database and department notes were studied. Conditions treated were pseudomyxoma peritoneii (PMP) and appendiceal cancer (23), mesothelioma (7), colorectal cancer (CRC, 15), ovarian cancer (6) and other forms of malignancy (9). Following cytoreductive surgery, early postoperative intraperitoneal chemotherapy (EPIC) was given in 47 procedures, five with added i.v. mitomycin C. In 34 procedures, heated intraperitoneal chemotherapy (HIPEC) was administered. A policy change was made from intravenous to intraperitoneal mitomycin C chemotherapy in December 2001. Peritoneal cancer index (PCI) was calculated for all procedures. Of the procedures, 23 had PCI &lt;/= 10, 37 had PCI of 11-20, and 11 had PCI &gt; 20. The median operation time was 9 h. Blood units transfused and length of hospital stay have declined. Mortality was 4/60 patients (6.7%), caused by pancytopenia and sepsis. Morbidity occurred in 28/71 procedures. The 3-year survival rate for the HIPEC group was 71% compared with 28% for the no HIPEC group. In the complete excision group, the 3-year survival rate was 52% compared with 13% for the incomplete excision group. The 3-year survival rate for PMP and appendiceal cancer was 74%. The 2-year survival rate for ovarian cancer was 67%, mesothelioma 57%, and CRC 50%, respectively. Morbidity is significantly associated with duration of surgery and units of blood transfused. Our findings are consistent with the international experience in patients treated with combined peritonectomy and HIPEC. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 1445-1433</identifier><identifier>EISSN: 1445-2197</identifier><identifier>DOI: 10.1111/j.1445-2197.2006.03579.x</identifier><language>eng</language><publisher>East Melbourne: Blackwell Publishing Ltd</publisher><subject>Cancer ; Chemotherapy ; Membranes ; Surgery ; Survival analysis</subject><ispartof>ANZ journal of surgery, 2006-03, Vol.76 (3), p.156-161</ispartof><rights>2006 Royal Australasian College of Surgeons</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Reema Hadi</creatorcontrib><creatorcontrib>Vanessa Saunders</creatorcontrib><creatorcontrib>Olga Utkina</creatorcontrib><creatorcontrib>Philip Clingan</creatorcontrib><creatorcontrib>Peter Kam</creatorcontrib><creatorcontrib>Links, Matthew</creatorcontrib><creatorcontrib>Morris, David L</creatorcontrib><title>ORIGINAL ARTICLE: REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY</title><title>ANZ journal of surgery</title><description>Peritoneal dissemination of malignancy is usually considered incurable. The purpose of the present study was to evaluate the efficacy of intraperitoneal chemohyperthermia and cytoreductive surgery. The present article is a retrospective review of prospectively recorded data in 60 patients who underwent 71 peritonectomy procedures between January 1996 and May 2004. Hospital records, a database and department notes were studied. Conditions treated were pseudomyxoma peritoneii (PMP) and appendiceal cancer (23), mesothelioma (7), colorectal cancer (CRC, 15), ovarian cancer (6) and other forms of malignancy (9). Following cytoreductive surgery, early postoperative intraperitoneal chemotherapy (EPIC) was given in 47 procedures, five with added i.v. mitomycin C. In 34 procedures, heated intraperitoneal chemotherapy (HIPEC) was administered. A policy change was made from intravenous to intraperitoneal mitomycin C chemotherapy in December 2001. Peritoneal cancer index (PCI) was calculated for all procedures. Of the procedures, 23 had PCI &lt;/= 10, 37 had PCI of 11-20, and 11 had PCI &gt; 20. The median operation time was 9 h. Blood units transfused and length of hospital stay have declined. Mortality was 4/60 patients (6.7%), caused by pancytopenia and sepsis. Morbidity occurred in 28/71 procedures. The 3-year survival rate for the HIPEC group was 71% compared with 28% for the no HIPEC group. In the complete excision group, the 3-year survival rate was 52% compared with 13% for the incomplete excision group. The 3-year survival rate for PMP and appendiceal cancer was 74%. The 2-year survival rate for ovarian cancer was 67%, mesothelioma 57%, and CRC 50%, respectively. Morbidity is significantly associated with duration of surgery and units of blood transfused. Our findings are consistent with the international experience in patients treated with combined peritonectomy and HIPEC. [PUBLICATION ABSTRACT]</description><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Membranes</subject><subject>Surgery</subject><subject>Survival analysis</subject><issn>1445-1433</issn><issn>1445-2197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpdT8FKw0AUXMSCtRX8hOLBW-K-ffve7h5DqDUQLNTew6bZgCE2tWvAzzdg8eBcZmCGYUaIFcgUJjx1KWhNiQJnUiUlpxLJuPT7Ssz_jOuLBo14I25j7KQEZkdzcb_dFZviNStX2W5f5OV6KWat72O4u_BCvD2v9_lLUm43RZ6VyYmsTZqWA5nagDbaaggaJB0oBOMtseeW2kar2sq2AVUHh7UHlOiRSTFzjQvx-Nt6Og-fY4hf1cd7PIS-98cwjLFS0jIS2Cn48C_YDeP5OC2rwFmF0z2FP-fGRWs</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Reema Hadi</creator><creator>Vanessa Saunders</creator><creator>Olga Utkina</creator><creator>Philip Clingan</creator><creator>Peter Kam</creator><creator>Links, Matthew</creator><creator>Morris, David L</creator><general>Blackwell Publishing Ltd</general><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20060301</creationdate><title>ORIGINAL ARTICLE</title><author>Reema Hadi ; Vanessa Saunders ; Olga Utkina ; Philip Clingan ; Peter Kam ; Links, Matthew ; Morris, David L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p588-df6e57b71474841e4105c5ee7a856a6f5fd42b80fd12be93ba1303a3652666b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Membranes</topic><topic>Surgery</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reema Hadi</creatorcontrib><creatorcontrib>Vanessa Saunders</creatorcontrib><creatorcontrib>Olga Utkina</creatorcontrib><creatorcontrib>Philip Clingan</creatorcontrib><creatorcontrib>Peter Kam</creatorcontrib><creatorcontrib>Links, Matthew</creatorcontrib><creatorcontrib>Morris, David L</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>ANZ journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reema Hadi</au><au>Vanessa Saunders</au><au>Olga Utkina</au><au>Philip Clingan</au><au>Peter Kam</au><au>Links, Matthew</au><au>Morris, David L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ORIGINAL ARTICLE: REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY</atitle><jtitle>ANZ journal of surgery</jtitle><date>2006-03-01</date><risdate>2006</risdate><volume>76</volume><issue>3</issue><spage>156</spage><epage>161</epage><pages>156-161</pages><issn>1445-1433</issn><eissn>1445-2197</eissn><abstract>Peritoneal dissemination of malignancy is usually considered incurable. The purpose of the present study was to evaluate the efficacy of intraperitoneal chemohyperthermia and cytoreductive surgery. The present article is a retrospective review of prospectively recorded data in 60 patients who underwent 71 peritonectomy procedures between January 1996 and May 2004. Hospital records, a database and department notes were studied. Conditions treated were pseudomyxoma peritoneii (PMP) and appendiceal cancer (23), mesothelioma (7), colorectal cancer (CRC, 15), ovarian cancer (6) and other forms of malignancy (9). Following cytoreductive surgery, early postoperative intraperitoneal chemotherapy (EPIC) was given in 47 procedures, five with added i.v. mitomycin C. In 34 procedures, heated intraperitoneal chemotherapy (HIPEC) was administered. A policy change was made from intravenous to intraperitoneal mitomycin C chemotherapy in December 2001. Peritoneal cancer index (PCI) was calculated for all procedures. Of the procedures, 23 had PCI &lt;/= 10, 37 had PCI of 11-20, and 11 had PCI &gt; 20. The median operation time was 9 h. Blood units transfused and length of hospital stay have declined. Mortality was 4/60 patients (6.7%), caused by pancytopenia and sepsis. Morbidity occurred in 28/71 procedures. The 3-year survival rate for the HIPEC group was 71% compared with 28% for the no HIPEC group. In the complete excision group, the 3-year survival rate was 52% compared with 13% for the incomplete excision group. The 3-year survival rate for PMP and appendiceal cancer was 74%. The 2-year survival rate for ovarian cancer was 67%, mesothelioma 57%, and CRC 50%, respectively. Morbidity is significantly associated with duration of surgery and units of blood transfused. Our findings are consistent with the international experience in patients treated with combined peritonectomy and HIPEC. [PUBLICATION ABSTRACT]</abstract><cop>East Melbourne</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/j.1445-2197.2006.03579.x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1445-1433
ispartof ANZ journal of surgery, 2006-03, Vol.76 (3), p.156-161
issn 1445-1433
1445-2197
language eng
recordid cdi_proquest_miscellaneous_20863518
source Wiley-Blackwell Read & Publish Collection
subjects Cancer
Chemotherapy
Membranes
Surgery
Survival analysis
title ORIGINAL ARTICLE: REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A55%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ORIGINAL%20ARTICLE:%20REVIEW%20OF%20PATIENTS%20WITH%20PERITONEAL%20MALIGNANCY%20TREATED%20WITH%20PERITONECTOMY%20AND%20HEATED%20INTRAPERITONEAL%20CHEMOTHERAPY&rft.jtitle=ANZ%20journal%20of%20surgery&rft.au=Reema%20Hadi&rft.date=2006-03-01&rft.volume=76&rft.issue=3&rft.spage=156&rft.epage=161&rft.pages=156-161&rft.issn=1445-1433&rft.eissn=1445-2197&rft_id=info:doi/10.1111/j.1445-2197.2006.03579.x&rft_dat=%3Cproquest%3E20863518%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p588-df6e57b71474841e4105c5ee7a856a6f5fd42b80fd12be93ba1303a3652666b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198232192&rft_id=info:pmid/&rfr_iscdi=true